In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A blockade. Since CD73 is known to be overexpressed in several human cancers and A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589050 | PMC |
| http://dx.doi.org/10.1080/2162402X.2015.1046675 | DOI Listing |
Publication Analysis
Top Keywords
anti-pd-1 therapy
8
cd73 potential
4
potential biomarker
4
biomarker anti-pd-1
4
therapy study
4
study tumoral
4
tumoral cd73
4
cd73 expression
4
expression limits
4
limits efficacy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!